Detalles de la búsqueda
1.
Rheumatoid arthritis and risk of osteoarticular infection and death following Staphylococcus aureus bacteraemia: A nationwide cohort study.
Rheumatology (Oxford)
; 2024 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38460189
2.
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.
Rheumatology (Oxford)
; 63(3): 751-764, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37314967
3.
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
Ann Rheum Dis
; 82(6): 820-828, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36813538
4.
Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries.
Rheumatology (Oxford)
; 62(2): 647-658, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35723604
5.
Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching.
Rheumatology (Oxford)
; 2023 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738257
6.
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.
Ann Rheum Dis
; 81(6): 789-797, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35318218
7.
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset.
Ann Rheum Dis
; 81(8): 1085-1095, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35470158
8.
Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark.
Rheumatology (Oxford)
; 61(9): 3711-3722, 2022 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34864891
9.
Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration.
Rheumatology (Oxford)
; 61(11): 4286-4296, 2022 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139178
10.
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries.
Rheumatology (Oxford)
; 61(9): 3647-3656, 2022 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34940795
11.
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
Rheumatology (Oxford)
; 61(9): 3799-3807, 2022 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34940840
12.
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Rheumatology (Oxford)
; 61(12): 4741-4751, 2022 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35323903
13.
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Ann Rheum Dis
; 80(11): 1445-1452, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34130984
14.
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Ann Rheum Dis
; 80(11): 1400-1409, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33926921
15.
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Ann Rheum Dis
; 80(11): 1410-1418, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34083206
16.
Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model.
Rheumatology (Oxford)
; 60(8): 3834-3844, 2021 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33493342
17.
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.
Rheumatology (Oxford)
; 60(1): 140-146, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32591790
18.
Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.
Rheumatology (Oxford)
; 60(8): 3635-3645, 2021 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33367900
19.
Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis.
Rheumatology (Oxford)
; 60(SI): SI3-SI12, 2021 10 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34146099
20.
Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
Rheumatology (Oxford)
; 59(8): 1949-1956, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31764977